HLA‐matched allogeneic anti‐CD19 CAR‐T therapy in treating a relapsed/refractory acute lymphoblastic leukemia patient with high tumor burden

The genetically engineered chimeric antigen receptor T cell (CAR‐T) therapy has shown remarkable clinical efficacy in the treatment of hematological malignancies. Nonetheless, it is difficult to harvest adequate autologous T cells to manufacture potent CAR‐T cell products in patients with high tumor...

Full description

Saved in:
Bibliographic Details
Published in:Immunomedicine 2022-06, Vol.2 (1), p.n/a
Main Authors: Huang, Yue, Yu, Qin, Yin, Elaine Tan Su, Wei, Guoqing, Wu, Wenjun, Chang, Alex H., Huang, He, Hu, Yongxian
Format: Article
Language:English
Subjects:
acute lymphoblastic leukemia
allogeneic chimeric antigen receptor T cells
central nervous system leukemia
cytokine release syndrome
HLA‐matched
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The genetically engineered chimeric antigen receptor T cell (CAR‐T) therapy has shown remarkable clinical efficacy in the treatment of hematological malignancies. Nonetheless, it is difficult to harvest adequate autologous T cells to manufacture potent CAR‐T cell products in patients with high tumor burden and prior tumor‐reductive treatment. Here we reported a relapsed/refractory acute lymphoblastic leukemia patient with high leukemia burden and central nervous system (CNS) involvement. The patient responded to donor‐derived HLA‐matched allogeneic CAR‐T treatment, with the achievement of quick complete remission. And for the first time, we revealed the development of a cerebral CRS in situ after allogeneic CAR‐T therapy.
ISSN:2510-5345
2510-5345
DOI:10.1002/imed.1032